Market Overview

UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight on Portfolio Quality

Related NPSP
3 Niche ETFs Breaking Out
Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results

Morgan Stanley initiated coverage on NPS Pharmaceuticals (NASDAQ: NPSP) with an Overweight rating and a $17 price target

Morgan Stanley commented, "NPS has two novel, late stage assets that we believe have key characteristics that to us indicate a high chance of commercial success despite the increasingly difficult reimbursement environment: a) strong efficacy and safety with a good disease impact, b) target diseases with a high unmet need and high acuity, and c) a competitive/unique drug profile. We believe the Street undervalues these novel assets, removing the long term leverage from this focused, orphan model."

NPS Pharmaceuticals closed at $9.52 on Wednesday.

Latest Ratings for NPSP

Jan 2015JP MorganMaintainsNeutral
Jan 2015BarclaysDowngradesOverweightEqual-weight
Jan 2015Canaccord GenuityDowngradesBuyHold

View More Analyst Ratings for NPSP
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (NPSP)

View Comments and Join the Discussion!

Partner Center